The Ohio State University, Parkinson's Center, 1581 Dodd Drive, Suite 371, Columbus, Ohio 43210, USA.
Expert Rev Neurother. 2001 Sep;1(1):43-51. doi: 10.1586/14737175.1.1.43.
Pramipexole is a dopamine agonist that was recently introduced for the treatment of both early and advanced Parkinson's disease. Pramipexole is a synthetic aminobenzothiazole compound with a high affinity to D(3) receptors. It directly stimulates dopamine receptors without requiring metabolic conversion. Pramipexole is rapidly absorbed with bioavailability greater than 90% and is actively secreted by the renal tubules. The drug's plasma half-life is 8-12 h. Shown to be safe and effective as add-on therapy, pramipexole can also be used as initial dopaminergic therapy in Parkinson's disease, delaying the introduction of levodopa thereby postponing levodopa's side-effects.
普拉克索是一种多巴胺激动剂，最近被引入用于治疗早期和晚期帕金森病。普拉克索是一种合成的氨基苯并噻唑化合物，对 D3 受体具有高亲和力。它直接刺激多巴胺受体，而不需要代谢转化。普拉克索吸收迅速，生物利用度大于 90%，并被肾小管主动分泌。该药物的血浆半衰期为 8-12 小时。作为附加疗法，普拉克索被证明是安全有效的，也可作为帕金森病的初始多巴胺能治疗药物，从而延迟左旋多巴的引入，推迟左旋多巴的副作用。
